Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 28
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Iovance Biotherapeutics Inc
IOVA
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$14.58
0.80
5.81%
Ult. Agg.: Oct 28, 8:09 AM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 8 giorni da adesso in gio nov 5th, prima dell'apertura del mercato
Iovance Biotherapeutics Financials
Iovance Biotherapeutics (IOVA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars
Iovance Biotherapeutics upgrades 2026 revenue guidance to $410 million-$420 million. Key technicals, analyst targets, and Amtagvi demand analyzed.
Vandana Singh
Crude Oil Down 1%; US Job Openings Fall In August
U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while NIVF plunged 77% and QURE fell 37%.
Avi Kapoor
PRO
Iovance Raises FY2026 Total Revenue Guidance From $350M-$370M To $410M-$420M
Benzinga Newsdesk
Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results
Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should know.
Evette Mitkov
PRO
Iovance Biotherapeutics Affirms FY2026 Sales Guidance of $350.000M-$370.000M vs $362.083M Est
Iovance Biotherapeutics (NASDAQ:IOVA) affirms FY2026 sales outlook from $350.000 million-$370.000 million to $350.000 million-$370.000 million vs $362.083 million estimate.
Benzinga Newsdesk
PRO
Iovance Biotherapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $99.313M Beat $87.832M Estimate
Benzinga Newsdesk
